The European LeukemiaNet: achievements and perspectives by Hehlmann, R. et al.
haematologica | 2011; 96(1)156
Introduction
Before the creation of the European LeukemiaNet (ELN),
there were a number of pre-existing networks in Europe that
were each individually developing diagnostic methodology,
running clinical trials and producing management guidelines.1
The main goal of the ELN was to create an environment in
which these organizations could work more closely together,
to harmonize their efforts and bring their advances to a wider
community in a more timely fashion.
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The only way to cure leukemia is by cooperative research. To
optimize research, the European LeukemiaNet integrates 105
national leukemia trial groups and networks, 105 interdiscipli-
nary partner groups and about 1,000 leukemia specialists
from 175 institutions. They care for tens of thousands of
leukemia patients in 33 countries across Europe. Their ulti-
mate goal is to cure leukemia. Since its inception in 2002, the
European LeukemiaNet has steadily expanded and has uni-
fied leukemia research across Europe. The European
LeukemiaNet grew from two major roots: 1) the German
Competence Network on Acute and Chronic Leukemias; and
2) the collaboration of European Investigators on Chronic
Myeloid Leukemia. The European LeukemiaNet has
improved leukemia research and management across Europe.
Its concept has led to funding by the European Commission
as a network of excellence. Other sources (European Science
Foundation; European LeukemiaNet-Foundation) will take
over when the support of the European Commission ends.
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leukemia, cure of leukemia, leukemia management guidelines.
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The first step was to bring together national leukemia
trial groups in an attempt to provide common definitions
and standards, to share information on ongoing and
planned trials, to work together to avoid duplicating activ-
ities, and to share the benefits of infrastructure. In a sec-
ond step, the interdisciplinary cooperation partners com-
mon to all leukemia trial groups were included (Figure 1).
The structure of the ELN is shown in Figure 2. 
Achievements
The ELN is a model of transnational cooperation.
Working together successfully has created a spirit of coop-
eration and mutual trust. 
The most visible results are: 1) those due to the cooper-
ative research projects and trials (Table 1) as reflected by a
large number of high impact publications; 2) the guide-
lines and management recommendations for virtually
every leukemia and interdisciplinary speciality (Table 2)
which have lain the groundwork for uniform definitions
and standards required for common clinical trials and proj-
ects; and 3) the website of ELN’s leukemia information
center for physicians, patients, their carers and the general
public (www.leukemia-net.org, www.leukemianet.eu). 
• The CML working-group (Work-Package WP 4) origi-
nated from the European Investigators on Chronic
Myeloid Leukemia (EI-CML) which itself met for the first
time in 1992. EI-CML has an impressive heritage of
accomplishments including meta-analyses, long-term
observation of cytogenetic responders, and the develop-
ment of a new prognostic CML-score (Euro-score). WP4
coordinates clinical trials between participating countries
and facilitates pan-European trials whenever feasible, e.g.
discontinuation of imatinib in stable complete molecular
responders. International management recommendations
were first published in 20062-3 and updated in 20094 (Table
2). WP4 was the first group to initiate a public-private
partnership with industry (Novartis) known as the
European Treatment and Outcome Study [EUTOS] for
CML: to build a European CML registry together with the
Registry working-group (WP17) (currently close to 5,000
patients registered and followed for outcome annually), to
standardize molecular and pharmacological monitoring
across Europe (58 laboratories in 29 countries standard-
ized for BCR-ABL monitoring) and to spread the informa-
tion to non-participating colleagues and countries by
annual educational symposia (five events since 2006),
training events for young hematologists, and lectures.
• The AML working-group (WP5) evolved from 16
European AML study-groups: MRC, GOELAMS, ALFA,
Polish AML-group, Russian AML-group, GIMEMA,
EORTC, HOVON, SAKK, Swedish AML-group, CET-
LAM, PETHEMA and four German AML study groups
cooperating in the German AML Intergroup to study cross
trial comparability with upfront randomization into a
common standard arm. The AML working-group current-
ly uses three approaches to improve the prognosis of
AML: 1) harmonization of criteria for the alignment of
protocols with stratification according to molecular and
cytogenetic risk markers, thus creating a platform for
meta-analyses; 2) establishment of a European network on
AML-management including geriatric assessment of elder-
ly AML which represents a poor risk population and the
largest proportion of AML patients;36 3) consensus
approach for risk adapted integration of transplantation in
AML balancing risk of disease versus risk of transplanta-
tion, including a newly defined frailty index. A European
network on management of de novo and relapsed acute
promyelocytic leukemia (APL) has been established.
Figure 1. Participants of
the European LeukemiaNet
according to their location.
According to the rules of
the European Commission,
only institutions can be
participants. One partici-
pating institution may com-
prise more than one
leukemia trial or interdisci-
plinary partner group.
Participating institutions
are listed in the Online
Supplementary Appendix. 
Management recommendations have been completed for
AML8 and APL9 (Table 2).
• The ALL working-group (WP6) brings together pedi-
atric and adult hematologists and has successfully used the
advent of advanced technologies for monitoring residual
disease to optimize the outcome of ALL. The rarity of ALL
has accelerated the formation of a European Working
Party for ALL (EWALL) and the performance of common
trials in several European countries. New drugs are under
study (nelarabine, clofarabine, herceptin, anti-CD22, dasa-
tinib, depocyte and forodesine), and a chemotherapy
backbone for elderly ALL was activated by three groups
(GMALL, GRAALL and PETHEMA). The latter have acti-
vated the first joint European trial with dasatinib for older
patients with Ph+ ALL. Supportive care and infection pro-
phylaxis were optimized on a European basis. EWALL has
recently been recognized as a scientific working-group
within the European Hematology Association (EHA),
thereby achieving synergy between the ELN and the EHA.
• The CLL working-group (WP7) has formally cooperat-
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Table 1. Key results.
• The network: Uniform definitions for diagnosis and treatment outcome; Common clinical trials and projects; Management recommendations for each
leukemia entity; Website to spread information on leukemia (www.leukemianet.eu); ELN-Foundation 
• CML (WP4): Pan-European trials; European CML-registry; Standardization of BCR-ABL monitoring 
• AML (WP5): Protocol alignments across Europe; Assessment of geriatric AML; Risk-adapted transplantation
• ALL (WP6): Pan-European trials ; MRD-guided management; MRD-monitoring by advanced technologies; Optimization of supportive care
• CLL (WP7): Protocol alignments; Chemoimmunotherapy; Study of rare subentities 
• MDS (WP8): European MDS-registry; European trials on all MDS-subtypes 
• CMPD (WP9): Harmonization of assay methods for JAK2-V617F; European trials e.g. on JAK2-inhibitors; Recognition of leukocytosis as a risk factor for
thrombosis 
• Morphology (WP10): Development of flow-cytometry for diagnosis and monitoring of MRD; Atlas of flow-cytometry
• Cytogenetics (WP11): Harmonization of techniques; Proposal for standardization; Identification of cryptic and complex aberrations and of minimal
chromosomal imbalances by aCGH and SNP-arrays
• MRD (WP12): Novel RQ-PCR assays for FIP1L1-PDGFRA and WT1; Standardization of assays for BCR-ABL and mutated JAK2; Computer-software 
for reporting MRD-data in a standardized fashion; Sequential monitoring for BCR-ABL, FIP1L1 PDGFRA and PML-RARA transcripts for guidance 
of treatment
• Gene profiling (WP13): Recognition of new patients subgroups by gene expression profiling; Standardization of techniques
• Stem cell transplantation (WP14): Assessment of key prognostic factors; Adaptation to elderly patients
• Infectious complications and supportive care (WP15): Care of neutropenic patients after stem cell transplantation and intensive chemotherapy;
Management of bacterial, viral and fungal infections in neutropenia; Monitoring of transfusion policy in Europe
Figure 2. Working-groups and organigram of the
European LeukemiaNet.
The European LeukemiaNet
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ed since the foundation of the European Research
Initiative for CLL (ERIC) in 2001. ERIC is an incorporated
legal entity (ERIC e.V.) in Germany, and in 2009 ERIC was
recognized as a scientific working-group within EHA. The
development of new potentially curative treatment
modalities for CLL is one of the long-term goals of
WP7/ERIC. Several protocol exchanges addressing
immunochemotherapy have been made between
European CLL-groups (German and French groups). Rare
subentities are addressed by combined
immunochemotherapy with fludarabine, mitoxantrone,
cyclophosphamide and alemtuzumab for T-prolympho-
cytic leukemia (T-PLL) (lead group Austria), with fludara-
bine, cyclophosphamide and rituximab for B-PLL (lead
group in Erfurt, Germany) and recommendations for stem
cell transplantation in T-PLL (lead group in Heidelberg and
Cologne, Germany). The harmonization of clinical proto-
cols between national CLL study-groups is ongoing.
Several guidelines on diagnostic procedures and therapy in
CLL have been published11-13 (Table 2).
• The MDS working-group (WP8) is the second WP to
start a European registry (EUMDS) with a private partner
(Novartis). About 650 low and intermediate risk-1 patients
have so far been registered. Extensive data on transfusions
and associated iron load are being collected. An extension
to high-risk patients is in progress. WP8 conducts
European trials on all MDS-subtypes with various agents
(lenalidomide, bortezomib, demethylating agents [azacy-
tidine, decitabine], cytarabine and growth factors: erythro-
poietin, GCSF, AMG531) and explores the impact of iron
chelation (deferasirox) on the prognosis of MDS.
Recommendations for diagnosis and treatment of MDS
Table 2. Recommendations and Guidelines
Topic Reference
CML management recommendations Baccarani et al., Blood 2006 ;108 :1809-202
Hehlmann et al., Lancet 2007;370:342-503
Baccarani et al., J Clin Oncol 2009;27:6041-514
CML molecular monitoring Müller et al., Leukemia 2009:1957-635
Hughes et al., Blood 2006;108:28-376
Branford et al., Leukemia 2006:1925-307
AML management recommendations Döhner et al., Blood 2009, 10;115:453-4748
APL management recommendations Sanz et al., Blood 2009;113:1875-919
APL molecular monitoring Grimwade et al.; J Clin Oncol 2009;27:3650-365810
CLL guidelines Hallek et al., Blood 2008;111:5446-5611
CLL molecular and flow-cytometric monitoring Ghia et al.; Leukemia 2007; 21:1-312
Rawstron et al., Leukemia 2007; 21 :956-6413
Evidence- and consensus-based European guidelines on MDS ELN Homepage 
http://www.leukemia-net.org/ content/leukemias/mds/recommendations 14
CMPD management recommendations (PV, ET, PMF) Barbui et al., J Clin Oncol ; in press15
Response criteria for ET and PV Barosi et al., Blood 2009;113:4829-3316
Definition of resistance and intolerance to hydroxyurea in PV and myelofibrosis Barosi et al., Br J Haematol 2010; 148:961-96317
Reference document for four- and five-color flow-cytometry Arnoulet et al. Cytometry B Clin Cytom 2010, 78:4-1018
Flow-cytometry in MDS van de Loosdrecht et al.; Haematologica 2009: 94:1124-3419
Consensual morphology collection ELN homepage: www.leukemianet.eu14
Proposals for standardization of cytogenetic analyses Haferlach et al., Genes Chromosomes Cancer 2007;46:494-920
FIP1L1-PDGFRA – recommendations for diagnosis & molecular monitoring Jovanovic et al., Blood 2007;109:4635-4021
Score et al. Leukemia 2009; 23:332-33922
WT1 PCR standardization Cilloni et al., J Clin Oncol 2009;27:5195-20123
Gene expression profiling recommendations Kohlmann et al., Br J Haematol 2008;142:802-724
Microarray analyses guidelines Staal et al., Leukemia 2006;20:1385-9225
Transplant-associated microangiopathy recommendations Ruutu et al., Haematologica 2007;92:95-10026
Stem cell transplantation recommendations
- in CLL Dreger et al., Leukemia 2007;21:12-727
- in MDS De Witte et al., Haematologica 2006;91:750-628
Recommendations for management of infections
- Quinolone prophylaxis for bacterial infections in afebrile neutropenia Bucaneve et al., EJC Supplements 2007 (Vol. 5, 5-12)29
- HSV, VZV and EBV Styczynski et al., Bone Marrow Transplant 2009;43:757-7030
- CMV, HHV-6, HHV-7 and HHV-8 Ljungman et al., Bone Marrow Transplant 2005;35, 737-74631
- Empirical antifungal therapy in febrile neutropenic patients Marchetti et al., EJC Supplements 2007 (Vol. 5, 32-42)32
- Primary antifungal prophylaxis Maertens et al., EJC Supplements 2007 (Vol. 5, 43-48)33
- Candida and Aspergillus Herbrecht et al., EJC Supplements 2007 (Vol. 5, 49-59)34
- Vaccination in stem cell transplant recipients Ljungman et al. Bone Marrow Transplant 2008;42:227-4035
are published on the ELN-website (Table 2). Also the MDS
working-group was recently recognized as a scientific
working-group within the EHA.
• The CMPD working-group (WP9) in cooperation with
groups in North America has explored the impact of JAK2
mutations on the diagnosis and therapy of myeloprolifera-
tive neoplasms (MPN). Harmonization of assay methods
for JAK2-V617F has been undertaken in close collaboration
with WP12. Several consensus protocols were published on
response criteria in essential thrombocythemia (ET) and
polycythemia vera (PV),16 and on the use of hydroxyurea in
PV and myelofibrosis17 (Table 2). A new risk factor (leuko-
cytosis) relevant for the management of thrombosis in
MPN has been identified. Management recommendations
for PV, ET and myelofibrosis have been completed.15
European trials are being developed to test proteasome- and
JAK2-inhibitors and other drugs (e.g. pomalidomide) in
myelofibrosis.
• A good example of the potential of networking is pro-
vided by the diagnostic working-groups (WP10-13) with
the Microarray Innovations in Leukemia (MILE) study. The
MILE-study, which was coordinated by WP13, involved 11
laboratories (7 from ELN, 3 from the US, one from
Singapore) and integrated data from morphology, cytoge-
netics, molecular genetics, immunophenotyping and gene
expression profiling from 3,334 patients to reveal new
patient subgroups with specific prognosis and survival.17,37
The MILE-study analyzes patients with all types of
leukemia in cooperation with WP4-9. Recommendations
for gene expression profiling and microarray analyses have
been published (Table 2).
• The morphology working-group (WP10) has devel-
oped recommendations for immunophenotyping, an atlas
of flow-cytometry of normal bone marrow and a consen-
sual morphology collection of hematopoietic cells posted
on the ELN-website (Table 2). WP10 has closely collabo-
rated with the clinical groups regarding the development
of flow-cytometry for the diagnosis and monitoring of
minimal residual disease,38 particularly in MDS.19
• A major challenge for the cytogenetics working-group
(WP 11) has been the harmonization of techniques and the
identification of cryptic and complex chromosome aberra-
tions. Consensus protocols for the diagnostic workup of
all types of leukemia and related syndromes, and a pro-
posal for standardization of cytogenetic analyses have
been developed20 (Table 2). In order to identify minimal
chromosomal imbalances not detectable by classical chro-
mosome banding or FISH analysis, comparative genomic
hybridization using arrays (aCGH) has been performed,
and loss of heterozygosity, a phenomenon often found in
leukemias, is studied by single nucleotide polymorphism
(SNP) arrays.
• The monitoring of minimal residual disease (MRD)
by WP12 has gained great importance by the advent of
well defined molecular markers with prognostic rele-
vance in virtually all leukemias. WP12 has developed
novel assays to increase the proportion of patients with
myeloid/myeloproliferative disorders who might benefit
from MRD monitoring such as RQ-PCR assays for
FIP1L1-PDGFRA21,22 in chronic eosinophilic leukemia and
assays to detect overexpression of the Wilms’ Tumor
gene (WT1) in AML23 (Table 2). This has been comple-
mented by standardization of established assays (e.g.
RQ-PCR for BCR-ABL5,6 and JAK2-V617F, in collabora-
tion with WP4 and WP9, respectively) and the develop-
ment of a tailor-made computer software-package to
standardize reporting of MRD-data. Using the optimized
ELN-WT1 assay, WP12 has shown that the kinetics of
disease response provide an independent prognostic fac-
tor in AML, and WP12 has highlighted, through studies
involving RQ-PCR detection of BCR-ABL, FIP1L1-
PDGFRA and PML-RARA transcripts,5,6,9,10,21,22 how
sequential MRD monitoring can be used to track
response to molecularly targeted therapies in a more
individualized approach.
• The stem cell transplantation working-group (WP14)
makes use of their productive collaboration with the
European Group for Blood and Marrow Transplantation
(EBMT). The main activities include regular surveys on
transplantation activity in Europe, recommendations for
the use of stem cell transplantation (Table 2), assessment
of key factors responsible for outcome39 and, as a current
focus, the adaptation of transplantation conditions to the
needs of elderly patients, mainly with AML and ALL. In
CML, an improvement in transplantation outcome has
been achieved with low transplantation mortality (<10%)
and 3-year survival rates of approximately 90% in chronic
phase and more than 50% in advanced phase patients.40
These favorable developments are mediated by improve-
ments in patient and donor selection, transplantation pro-
cedures and supportive care. 
• The Working-group on management of infectious
complications, infection prophylaxis and supportive care
(WP15) has addressed the management of neutropenic
patients after stem cell transplantation or intensive
chemotherapy. Recommendations on the diagnosis and
management of bacterial, viral and fungal infections have
been published (Table 2). Guidelines for the management
of hepatic, respiratory and adenovirus infections are in
preparation as well as protocols to assess the genetic risks
for fungal infections and to monitor transfusion policy in
Europe.
Perspectives
It is not easy to measure the individual contribution of
the ELN towards the general advancement of research
and improvement of prognosis in the field of leukemia.
However, we can point to the number of common clinical
trials, projects and publications, and the steadily increas-
ing numbers of ELN participants to demonstrate its suc-
cess. Various ELN-studies have been completed41,42 and
ELN-criteria are widely used.43-45 A number of activities
point to sustainability and further development of the
ELN.
• Common observational and interventional studies on
a European level continue in realization of the need for
cooperation on rare diseases such as the leukemias.
• Leukemia-registries will expand, answer questions,
and promote progress of leukemia research. Multiple
public-private partnerships are envisaged.
• New projects and trials will be defined by working-
groups and delivered with support by the ELN-
Foundation, the European Science Foundation and other
sources. 
• In view of current legislation which threatens treat-
ment optimization studies, the ELN-Foundation might
serve as ‘Sponsor’. The ELN supports every effort to
achieve a modification of the European drug legislation
for treatment optimization studies.
• Due to its structured and long-term cooperation, the
R. Hehlmann et al.
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ELN is likely to have a durable impact on leukemia
research in Europe. Infrastructure and the productive col-
laboration provided by the ELN have provided a valuable
contribution to progress in the field of leukemia. 
• By promoting cooperation over the competition that
is necessary for good research, the ELN provides a com-
petitive advantage for all participants to the benefit of
every patient with leukemia worldwide. 
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